Lv1
50 积分 2022-12-09 加入
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?
2个月前
已完结
Fluorinated materials for in vivo oxygen transport (blood substitutes), diagnosis and drug delivery
2个月前
已完结
JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models
2个月前
已完结
Zongertinib in Previously Treated HER2 -Mutant Non-Small-Cell Lung Cancer
3个月前
已完结
Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies
5个月前
已完结
Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations
5个月前
已完结
Clinical characteristics and medical service utilization of lung cancer in China, 2005–2014: Overall design and results from a multicenter retrospective epidemiologic survey
5个月前
已完结
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
5个月前
已完结
EP.08D.08 Aumolertinib as Neoadjuvant Therapy for EGFR M+ NSCLC: A Subcohort Analysis of PURPOSE Trial Data Updated
5个月前
已关闭
Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
6个月前
已完结
皖公网安备34019202002308
